Revagenix – a biopharmaceutical company dedicated to the discovery and development of novel antibiotics – recently announced the appointment of Cristina Larkin, Bruce Montgomery, MD, and Michael Lamprecht, Ph.D., to its board of directors in connection with closing its Series B funding round from core investors Tenmile and Novo Holdings. Ryan Cirz, PhD, Chief Executive Officer, and director, highlighted the developments as essential milestones in the company’s growth that will enable its mission of creating life-changing antibiotics through scientific innovation and strategic leadership.
The Series B funding complements ongoing funding from two product development contracts with the National Institute of Allergy and Infectious Diseases (NIAID). And Revagenix Chief Operating Officer and Director Andrew McCandlish, PhD, emphasized the importance of public and private support for the field.
As part of this transition, two former directors, Andrew Calabrese and Aleks Engel, will step down from the board.
Revagenix’s executive team is rounded out by Chief Operating Officer (COO) and Director Andrew McCandlish, PhD, Vice President of Pharmaceutical Development Mick Hurrey, PhD, and Vice President of Development Daniel Cloutier, PharmD. And the company’s board is chaired by Tina Marriott, President and Chief Operating Officer of Recursion.
KEY QUOTES:
“Antibiotic resistance represents one of the most significant public health crises of our time and is a major unmet medical need for patients with drug-resistant infections. We are pleased and honored to have our new directors join the Revagenix board. These additions will bolster and complement our leadership team’s extensive experience in anti-infectives to address the scientific and commercial challenges in the field.”
“Andrew was one of the company’s original founders and a critical part of the team as we worked to navigate the Company’s formation in 2019, including completing the first financing and initiating R&D activities in 2020 during the COVID-19 pandemic. We are forever grateful for Andrew’s contributions and would not be where we are today without him. Aleks was the first investor to believe in the mission and vision for how Revagenix would navigate one of the most challenging financial environments in biotech today, and we thank him for that endorsement and look forward to proving him right.”
“With the support of its investors, partners, and the strengthened capabilities of its leadership team, the company is well-positioned to address the complex challenges in the development of new antibiotic therapies. We are excited to share our story more in depth in the future. First, we need to get back to work—patients are counting on us.”
— Dr. Cirz
“Our decision to lead the Series B financing is a testament to our belief in the Company’s vision and the potential of its innovative antibiotic programs,” Dr. Burnell said. “We are confident that Revagenix, with its strong leadership and focused approach, is well-positioned to bring critical solutions to a global health challenge.”
— Tenmile managing director Steve Burnell, PhD
“The recent financing, in conjunction with our ongoing collaborations with NIAID, positions us to advance multiple home-grown programs with substantive differentiation into the clinic. This continued partnership with NIAID is crucial in the current market environment, providing essential support for our antibiotic research and development programs.”
— Dr. McCandlish
“Our continued support reflects our confidence in the Company’s strategic direction and the deep expertise of its team. We are particularly pleased that Bruce Montgomery, MD, with his deep scientific and executive experience in the development and commercialization of antibiotics, will continue to represent Novo Holdings on the board. Dr. Montgomery’s expertise is invaluable to our shared vision. We are proud to be part of Revagenix’s journey and eagerly anticipate the impactful innovations they are poised to bring to the healthcare sector.”
— Novo Holdings partner Aleks Engel
